Integration of patient-reported outcomes (PROs) for personalized symptom management in "real-world" oncology practices: a population-based cohort comparison study of impact on healthcare utilization.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 08 08 2019
accepted: 16 01 2020
pubmed: 6 2 2020
medline: 21 10 2020
entrez: 6 2 2020
Statut: ppublish

Résumé

The use of patient-reported outcomes (PROs) for routine cancer distress screening is endorsed globally as a quality-care standard. However, there is little research on the integration of PROs in "real-world" oncology practices using implementation science methods. The Improving Patient Experience and Health Outcome Collaborative (iPEHOC) intervention was established at multisite disease clinics to facilitate the use of PRO data by clinicians for precision symptom care. The aim of this study was to examine if patients exposed to the intervention differed in their healthcare utilization compared with contemporaneous controls in the same time frame. We used a PRE- and DURING-intervention population cohort comparison study design to estimate the effects of the iPEHOC intervention on the difference in difference (DID) for relative rates (RR) for emergency department (ED) visits, hospitalizations, psychosocial oncology (PSO), palliative care visits, and prescription rates for opioids and antidepressants compared with controls. A small significantly lower Difference in Difference (DID) (- 0.223) in the RR for ED visits was noted for the intervention compared with controls over time (0.947, CI 0.900-0.996); and a DID (- 0.0329) for patients meeting ESAS symptom thresholds (0.927, CI 0.869-0.990). A lower DID in palliative care visits (- 0.0097), psychosocial oncology visits (- 0.0248), antidepressant prescriptions (- 0.0260) and an increase in opioid prescriptions (0.0456) in the exposed population compared with controls was also noted. A similar pattern was shown for ESAS as a secondary exposure variable. Facilitating uptake of PROs data may impact healthcare utilization but requires examination in larger scale "real-world" trials.

Sections du résumé

BACKGROUND BACKGROUND
The use of patient-reported outcomes (PROs) for routine cancer distress screening is endorsed globally as a quality-care standard. However, there is little research on the integration of PROs in "real-world" oncology practices using implementation science methods. The Improving Patient Experience and Health Outcome Collaborative (iPEHOC) intervention was established at multisite disease clinics to facilitate the use of PRO data by clinicians for precision symptom care. The aim of this study was to examine if patients exposed to the intervention differed in their healthcare utilization compared with contemporaneous controls in the same time frame.
METHODS METHODS
We used a PRE- and DURING-intervention population cohort comparison study design to estimate the effects of the iPEHOC intervention on the difference in difference (DID) for relative rates (RR) for emergency department (ED) visits, hospitalizations, psychosocial oncology (PSO), palliative care visits, and prescription rates for opioids and antidepressants compared with controls.
RESULTS RESULTS
A small significantly lower Difference in Difference (DID) (- 0.223) in the RR for ED visits was noted for the intervention compared with controls over time (0.947, CI 0.900-0.996); and a DID (- 0.0329) for patients meeting ESAS symptom thresholds (0.927, CI 0.869-0.990). A lower DID in palliative care visits (- 0.0097), psychosocial oncology visits (- 0.0248), antidepressant prescriptions (- 0.0260) and an increase in opioid prescriptions (0.0456) in the exposed population compared with controls was also noted. A similar pattern was shown for ESAS as a secondary exposure variable.
CONCLUSION CONCLUSIONS
Facilitating uptake of PROs data may impact healthcare utilization but requires examination in larger scale "real-world" trials.

Identifiants

pubmed: 32020357
doi: 10.1007/s00520-020-05313-3
pii: 10.1007/s00520-020-05313-3
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

4933-4942

Références

Holland J, Watson M, Dunn J (2011) The IPOS new international standard of quality Cancer care: integrating the psychosocial domain into routine cancer care. Psycho-Oncology 20:677–680
doi: 10.1002/pon.1978
Alemayehu D, Cappelleri JC (2012) Conceptual and analytic considerations toward the use of patient-reported outcomes in personalized medicine. Am Health Drug Benefits 5(5):310–317
pubmed: 24991329 pmcid: 4046457
PROMs Background Document, Canadian Institute for Health Information. PROMs Forum Feb 2015. https://www.cihi.ca/sites/default/files/document/proms_background_may21_en-web.pdf
Chen J, Ou L, Hollis SJ (2013) A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organizations in an oncologic setting. BMC Health Serv Res 11(13):211
doi: 10.1186/1472-6963-13-211
Yang L, Manhas D, Howard A et al (2014) Patient-reported outcome use in oncology: a systematic review of the impact on patient-clinician communication. Support Care Cancer 26:41–60
doi: 10.1007/s00520-017-3865-7
Kotronoulas G, Kearney N, Maguire R, Harrow A, di Domenico D, Croy S, MacGillivray S (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32(14):1480–1501
doi: 10.1200/JCO.2013.53.5948
Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198
doi: 10.1001/jama.2017.7156
Denis F, Lethrosne C, Pourel N et al (2017) Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst 109:1460–2105
doi: 10.1093/jnci/djx029
Stover A, Irwin DE, Chen RC et al (2015) Integrating patient-reported measures into routine cancer care: cancer patients’ and clinicians’ perceptions of acceptability and value. EGEMS The Electronic Journal for Electronic Health Data and Methods (Wash DC) 3(1):1169. https://doi.org/10.13063/2327-9214.1169
Anachkova M, Donelson S, Ska Licks AM et al (2018) Exploring the implementation of patient-reported outcome measures in cancer care: need for more ‘real-world’ evidence results in the peer reviewed literature. J Patient-Reported Outcomes 2(64):1–21
Howell D, Hack TF, Green E, Fitch M (2014) Cancer distress screening data: translating knowledge into clinical action for a quality response. Palliat Supp Care 12(1):39–51
doi: 10.1017/S1478951513000382
Mitchell S, Chambers D (2017) Leveraging implementation science to improve cancer care delivery and patient outcomes. JOP 13(8):523–539
doi: 10.1200/JOP.2017.024729
Greenhalgh J, Long AF, Flynn R (2005) The use of patient reported outcome measures in routine clinical care: lack of impact or lack of theory? Soc Sci Med 60:833–843
doi: 10.1016/j.socscimed.2004.06.022
Li M, Macedo L, Crawford S et al (2016) Easier said than done: keys to successful implementation of the Distress Assessment and Response Tool (DART) program. JOP 2(5):e513–e526
doi: 10.1200/JOP.2015.010066
Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, Liberty J (2015) Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 26(9):1846–1858
doi: 10.1093/annonc/mdv181
Santana MJ, Haverman L, Absolom K (2015) Training clinicians in how to use patient-reported outcome measures in routine clinical practice. Qual Life Res 24(7):1701–1718
doi: 10.1007/s11136-014-0903-5
Pereira J, Green E, Molloy S et al (2014) Population-based standardized symptom screening: Cancer Care Ontario’s Edmonton Symptom Assessment System and performance status initiatives. JOP 10(3):212–214
doi: 10.1200/JOP.2014.001390
Seow H, Sussman J, Martelli-Reid L et al (2012) Do high symptom scores trigger clinical actions? An audit after implementing electronic symptom screening. JOP 8(6):e142–e148
doi: 10.1200/JOP.2011.000525
Graham I, Logan J, Harrison M, Straus S, Tetroe J, Caswell W, Robinson N (2006) Lost in knowledge translation: time for a map? J Contin Educ Heal Prof 26:3–24
doi: 10.1002/chp.45
Hiatt JM (2006) ADKAR: a model for change in business, government and our community. Prosci Learning Center Publications, Loveland
Gagliardi AR, Berta W, Kothari A, Boyko J, Urquart R (2016) Integrated knowledge translation (IKT) in health care: a scoping review. Implement Sci 17(11):38
Thomson O’Brien MA, Oxman AD, Haynes RB et al (2000) Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2:CD003030
Miech EJ, Rattray NA, Flanagan ME, Damschroeder L, Schmid AA, Damush TM (2018) Inside help: an integrative review of champions in healthcare-related implementation. SAGE Open Med 6:1–11
doi: 10.1177/2050312118773261
Stewart M, Brown JB, Weston WW, McWhinney IR, McMillan CI, Freeman TR (2014) Patient-centered medicine: transforming the clinical method. CRC Press, Taylor & Francis Group, Boca Raton
Howell D, Keller-Olaman S, Oliver T et al. A pan-Canadian practice guideline: screening, assessment and care of psychosocial distress (depression, anxiety) in adults with cancer. Canadian Partnership Against Cancer (Cancer Journey Action Group) and the Canadian Association of Psychosocial Oncology. August 2010. Available at http://www.capo.ca/pdf/ENGLISH_Depression_Anxiety_Guidelines_for_Posting_Sept2011.pdf . Accessed March 30, 2017
Watanbe SM, Nekolaichuk C, Beaumont C et al (2011) A multicenter study comparing to numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manag 41:456–468
doi: 10.1016/j.jpainsymman.2010.04.020
Dudgeon D, King S, Howell D, Green E, Gilbert J, Hughes E, Lalonde B, Angus H, Sawka C (2011) Cancer Care Ontario’s experience with implementation of routine physical and psychological symptom distress screening. Psychooncology 21(4):357–364
doi: 10.1002/pon.1918
Gilbert J, Howell D, King S, Sawka C, Hughes E, Angus H, Dudgeon D (2012) Quality improvement in cancer symptom assessment and control: the provincial palliative care integration project (PPCIP). J Pain Symptom Manag 43(4):663–678
doi: 10.1016/j.jpainsymman.2011.04.028
Daut RL, Cleeland CS, Flanery RC (1983) Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17:197–210
doi: 10.1016/0304-3959(83)90143-4
Okuyama T, Akechi T, Kugaya A, Okamura H, Shima Y, Maruguchi M, Hosaka T, Uchitomi Y (2000) Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manag 19(1):5–14
doi: 10.1016/S0885-3924(99)00138-4
Spitzer RL, Kroenke K, Williams JB, Lowe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092–1097
doi: 10.1001/archinte.166.10.1092
Kroenke K, Spitzer R, Williams W (2001) The PHQ-9: validity of a brief depression severity measure. JGIM 16:606–616
doi: 10.1046/j.1525-1497.2001.016009606.x
Bultz BD, Groff SL, Fitch M, Blais MC, Howes J, Levy K, Mayer C (2011) Implementing screening for distress, the 6th vital sign: a Canadian strategy for changing practice. Psycho-Oncology 28:463–469
doi: 10.1002/pon.1932
Wright EP, Kiely M, Johnston C, Smith AB, Cull A, Selby PJ (2005) Development and evaluation of an instrument to assess social difficulties in routine oncology practice. Qual Life Res 14:373–386
doi: 10.1007/s11136-004-5332-4
Selby D, Chakraborty A, Myers J, Saskin R, Mazzotta P, Gill A (2011) High scores on the Edmonton symptom assessment scale identify patients with self-defined high symptom burden. J Palliat Med 14:1309–1316
doi: 10.1089/jpm.2011.0187
Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CC (2013) Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symp Manage 45(5):1083–1093
doi: 10.1016/j.jpainsymman.2012.06.007
Bagha SM, Macedo A, Jacks LM, Lo C, Zimmermann C, Rodin G, Li M (2013) The utility of the Edmonton symptom assessment system in screening for anxiety and depression. Eur J Cancer Care 22(1):60–69
doi: 10.1111/j.1365-2354.2012.01369.x
Iron K, Zagorski BM, Sykora K, Manuel DG (2008) Living and dying in ontario: An opportunity for improved health information. ICES investigative report Toronto: Institute for Clinical Evaluative Sciences
Discharge Abstracts Database of CIHI (DAD) Canadian Institute for Health Information (2012) Data quality documentation, discharge abstract database — current year information. CIHI, Ottawa, ON http://www.cihi.ca . Accessed on April 2016
Canadian Institute for Health Information: CIHI Data Quality Study of Ontario Emergency Department Visits for Fiscal Year 2007, in Ottawa, Ontario, 2007
Symptom assessment and management Cancer Quality Council of Ontario www.csqi.on.ca/cms/one.aspx?portalId=258922&pageId=272723#.UtXPvvRDsV0
Cancer Activity Level Reporting (ALR) database. Cancer Care Ontario's Data Book - 2016-2017
Ontario Drug Benefit (ODB) Database, Ontario Ministry of Health and Long Term Care
Barbera LC, Seow H, Husain A, Howell D et al (2011) How often are opioids prescribed for cancer patients reporting pain? Results of a population-based analysis. JCO 29(15):6084
doi: 10.1200/jco.2011.29.15_suppl.6084
Abadie, A. (2005). Semiparametric difference-in-differences estimators. Rev Econ Stud 72 (1):1–19. https://doi.org/10.1111/0034-6527.0032
Barbera L, Sutradhar R, Howell D et al (2015) Does routine symptom screening with ESAS decrease ED visits in breast cancer patients undergoing adjuvant chemotherapy? Support Care Cancer 23:3025–3032
doi: 10.1007/s00520-015-2671-3
Butow P, Price MA, Shaw JM, Turner J, Clayton JM, Grimison P, Rankin N, Kirsten L (2015) Clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients: Australian guidelines. Psychooncology 24:987–1001
doi: 10.1002/pon.3920
Mittman BS (2004) Creating the evidence base for quality improvement Collaboratives. Ann Int Med 140:897–901
doi: 10.7326/0003-4819-140-11-200406010-00011
Greene J, Hibbard JH (2012) Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med 27:520–526
doi: 10.1007/s11606-011-1931-2

Auteurs

Doris Howell (D)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Madeline Li (M)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Rinku Sutradhar (R)

ICES, Toronto, Ontario, Canada.
Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Sumei Gu (S)

ICES, Toronto, Ontario, Canada.

Javaid Iqbal (J)

ICES, Toronto, Ontario, Canada.

Mary Ann O'Brien (MA)

Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.

Hsien Seow (H)

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

Deborah Dudgeon (D)

Department of Medicine and Oncology, Queen's University, Kingston, Ontario, Canada.

Clare Atzema (C)

ICES, Toronto, Ontario, Canada.
Department of Emergency Services, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Craig C Earle (CC)

ICES, Toronto, Ontario, Canada.
Department of Medicine, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Carlo DeAngelis (C)

Department of Pharmacy, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

Jonathan Sussman (J)

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

Lisa Barbera (L)

ICES, Toronto, Ontario, Canada. lisa.barbera@albertahealthservices.ca.
Tom Baker Cancer Centre, Calgary, Alberta, Canada. lisa.barbera@albertahealthservices.ca.
Division of Radiation Oncology, University of Calgary and Tom Baker Cancer Centre, Calgary, Canada. lisa.barbera@albertahealthservices.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH